SEC Tracker
Get the app

Actuate Therapeutics ACTU

Actuate Therapeutics Q3 FY24: net loss $6.0M; diluted EPS −$0.55

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Actuate Therapeutics reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$6.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.55No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$13.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$9.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Actuate Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lite Strategy LITS public float $43M, Dec 31, 2025
  2. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025
  3. Fortress Biotech FBIO public float $44M, Jun 30, 2025
  4. CervoMed CRVO public float $40M, Jun 30, 2025
  5. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025